Neuroendocrine Tumors | Topics

 
Kelley Lauren Coffman, MD, on Key Takeaways from a Study of 177Lu-DOTATATE in Well-Differentiated, High-Grade NETs
February 10, 2021

The hospitalist at Memorial Sloan Kettering Cancer Center discussed what she believes is most important for practicing oncologists to understand about a study of 177Lu-DOTATATE in well-differentiated, high-grade neuroendocrine tumors.

Kelley Lauren Coffman, MD, on the Next Steps for a Study of 177Lu-DOTATATE in Well-Differentiated, High-Grade NETs
February 07, 2021

The hospitalist at Memorial Sloan Kettering Cancer Center spoke about the next steps for a study which evaluated patients with well-differentiated, high-grade neuroendocrine tumors (NETs) who were treated with 177Lu-DOTATATE.

Kelley Lauren Coffman, MD, on a Study of 177Lu-DOTATATE in Well-Differentiated, High-Grade NETs
February 03, 2021

The hospitalist at Memorial Sloan Kettering Cancer Center highlighted important takeaways from a study which evaluated the use of 177Lu-DOTATATE in patients with well-differentiated, high-grade neuroendocrine tumors.